Zombie Aqua™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
1-Zombie_Aqua_Viability_Dye_nowash_050713
One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • 1-Zombie_Aqua_Viability_Dye_nowash_050713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • b-Zombie_Aqua_Viability_Dye_032713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • c-Zombie_Aqua_Viability_Dye_012721
    HeLa cells were treated with 20% EtOH for 20 seconds, washed twice with PBS, and then were left to recover for five minutes with cell culture media in 37°C. The cells were stained with Zombie Aqua™ (1:1000) (cyan) for 15 minutes and then fixed with 1% paraformaldehyde (PFA) for ten minutes. Nuclei were counterstained with DRAQ5 (Red) for five minutes. The image was captured with 40X objective.
See Zombie Aqua™ spectral data
Cat # Size Price Quantity Check Availability Save
423101 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423102 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Aqua™ is a polar, water-soluble dye providing very bright green fluorescence, making it suitable for use in multi-color detection.
 

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie Aqua™ Fixable Viability Kit is composed of lyophilized Zombie Aqua™ dye and anhydrous DMSO. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved. 100 tests = 1 vial of Zombie Aqua™ + DMSO, 500 tests = 5 vials of Zombie Aqua™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Aqua™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC, ICFC - Quality tested
ICC - Verified

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunofluorescence microscopy, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

 

Excitation Laser
Violet Laser (405 nm)
Application Notes

Zombie Aqua™ dye is excited by the violet laser and has a maximum emission of 516 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Aqua™ dye has similar emission to Brilliant Violet 510™.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Aqua™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie Aqua™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Aqua™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Aqua™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie Aqua™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Aqua™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Aqua™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Aqua™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Aqua™.
Additional Product Notes

View more applications data using this product to validate Veri-Cells™ lyophilized control cells and to study dendritic cell subsets.

Application References

(PubMed link indicates BioLegend citation)
  1. Vom Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  2. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  3. Price PJ, et al. 2014. J Virol. 88:10840. PubMed
  4. Schmid MA, et al. 2014. PLoS Pathog. 10:1004541. PubMed
  5. Cohen SB, et al. 2015. J Immunol. 194:210. PubMed
  6. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  7. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  8. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  9. Tzeng A, et al. 2015. PNAS. 112:3320. PubMed
  10. Peres AG, et al. 2015. Infect Immun. 83:1587. PubMed
  11. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
Product Citations
  1. Bussières-Marmen S, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.72. PubMed
  2. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  4. Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed
  5. Tasker C, et al. 2021. AAPS J. 23:26. PubMed
  6. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  7. Kim J, et al. 2021. Front Cell Neurosci. 638098:15. PubMed
  8. Nuccitelli R, et al. 2017. J Immunother Cancer . 10.1186/s40425-017-0234-5. PubMed
  9. Kaczanowska S, et al. 2017. Cancer Res. . 10.1158/0008-5472.CAN-17-0653. PubMed
  10. Gálvez-Cancino F, et al. 2018. Oncoimmunology. 7:e1442163. PubMed
  11. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  12. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  13. Ko J, et al. 2022. Nat Biotechnol. 40:1654. PubMed
  14. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  15. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  16. Bermea KC, et al. 2022. J Vis Exp. . PubMed
  17. Jia L, et al. 2022. Gut Microbes. 14:2117503. PubMed
  18. Frost JN, et al. 2022. Sci Adv. 8:eabq5384. PubMed
  19. Schuhmacher J, et al. 2022. Cells. 11:. PubMed
  20. Cruz-Reséndiz A, et al. 2022. Front Immunol. 13:1057499. PubMed
  21. Johnson SD, et al. 2022. Front Immunol. 13:1001727. PubMed
  22. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  23. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  24. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  25. Yang Y, et al. 2023. MBio. 14:e0328522. PubMed
  26. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  27. Jun SH, et al. 2023. Nat Commun. 14:982. PubMed
  28. Fernandes S, et al. 2023. iScience. 26:106071. PubMed
  29. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  30. Medina S, et al. 2023. Water (Basel). 15:. PubMed
  31. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  32. Xu K, et al. 2023. Elife. 12:. PubMed
  33. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  34. Zhang J, et al. 2023. Front Immunol. 14:1091541. PubMed
  35. Harpur CM, et al. 2023. Clin Transl Immunology. 12:e1443. PubMed
  36. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  37. Ahmed O, et al. 2023. Bioelectron Med. 9:6. PubMed
  38. Freitag PC, et al. 2023. Mol Ther Methods Clin Dev. 29:120. PubMed
  39. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  40. Madar J, et al. 2023. Nat Commun. 14:2158. PubMed
  41. Consonni FM, et al. 2023. Front Immunol. 14:1168455. PubMed
  42. Fang Y, et al. 2023. Front Immunol. 14:1162004. PubMed
  43. Chaturvedi S, et al. 2023. Cell. 186:2036. PubMed
  44. Ximerakis M, et al. 2023. Nat Aging. 3:327. PubMed
  45. Liao Y, et al. 2023. ACS Omega. 8:15217. PubMed
  46. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  47. Liu JC, et al. 2023. Int J Mol Sci. 24:. PubMed
  48. Tang L, et al. 2023. Front Immunol. 14:1145441. PubMed
  49. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  50. Malik JR, et al. 2023. Int J Mol Sci. 24:. PubMed
  51. Feng X, et al. 2023. Nat Commun. 14:3208. PubMed
  52. Komoto S, et al. 2023. Cancers (Basel). 15:. PubMed
  53. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  54. Rueschenbaum S, et al. 2021. Front Immunol. 11:581352. PubMed
  55. Fantone K, et al. 2021. Pathogens. 10:. PubMed
  56. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  57. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  58. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  59. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  60. Castle AR, et al. 2022. PLoS One. 17:e0269342. PubMed
  61. Healy LM, et al. 2020. Glia. 68:811. PubMed
  62. Buchanan MW, et al. 2021. J Orthop Res. 39:1710. PubMed
  63. Eiva MA, et al. 2022. Eur J Immunol. 52:96. PubMed
  64. Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed
  65. Herz J, et al. 2021. Neuron. 109:3609. PubMed
  66. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  67. Miek L, et al. 2022. Immunology. 166:47. PubMed
  68. Wolf B, et al. 2022. Immunology. 166:380. PubMed
  69. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  70. Shcheynikov N, et al. 2022. Hepatology. 76:1248. PubMed
  71. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  72. Adam-Artigues A, et al. 2022. Sci Adv. 8:eabk2746. PubMed
  73. Yang K, et al. 2022. Sci Immunol. 7:eabn2888. PubMed
  74. Sugimoto S, et al. 2022. Nat Metab. 4:775. PubMed
  75. Ma T, et al. 2022. Elife. 11: . PubMed
  76. Benedetti V, et al. 2022. Sci Adv. 8:eabn3986. PubMed
  77. Guasconi L, et al. 2022. J Fungi (Basel). 8: . PubMed
  78. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  79. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  80. Martínez-Sabadell A, et al. 2022. Cell Rep. 41:111430. PubMed
  81. Gao Y, et al. 2022. Cell Res. 32:1086. PubMed
  82. Dhar R, et al. 2022. Int J Mol Med. 50: . PubMed
  83. Balood M, et al. 2022. Nature. 611:405. PubMed
  84. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  85. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  86. Rico-Llanos G, et al. 2022. Front Immunol. 13:1054962. PubMed
  87. Chen W, et al. 2022. Front Immunol. 13:1046426. PubMed
  88. Zia S, et al. 2022. Mol Neurodegener. 17:82. PubMed
  89. Zhuang L, et al. 2022. J Am Heart Assoc. 11:e027228. PubMed
  90. Pleuger C, et al. 2022. Elife. 11: . PubMed
  91. Shen W, et al. 2023. Dis Model Mech. 16: . PubMed
  92. Perveen R, et al. 2023. Hum Cell. 36:583. PubMed
  93. Krammer S, et al. 2022. Cells. 12: . PubMed
  94. Chan L, et al. 2022. Cells. 12: . PubMed
  95. Cousin N, et al. 2022. Cells. 12: . PubMed
  96. Rice CM, et al. 2023. Life Sci Alliance. 6: . PubMed
  97. Zhao Q, et al. 2023. Nutrients. 15: . PubMed
  98. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  99. Ai L, et al. 2023. Cell Discov. 9:9. PubMed
  100. Gong HH, et al. 2023. Front Immunol. 13:1089064. PubMed
  101. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  102. Liu G, et al. 2023. Commun Biol. 6:102. PubMed
  103. Li H, et al. 2023. Front Immunol. 13:1056447. PubMed
  104. Lutz EA, et al. 2022. PNAS Nexus. 1:pgac244. PubMed
  105. Badenes M, et al. 2023. Life Sci Alliance. 6: . PubMed
  106. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  107. Kang J, et al. 2023. JCI Insight. 8: . PubMed
  108. Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed
  109. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  110. Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed
  111. Li Y, et al. 2022. Brain Behav Immun. 101:1. PubMed
  112. Ryan CB, et al. 2022. Neurobiol Dis. 163:105608. PubMed
  113. Fahrner JE, et al. 2022. Cancer Discov. 12:958. PubMed
  114. Blair TC, et al. 2022. Life Sci Alliance. 5:. PubMed
  115. Seki SM, et al. 2020. Sci Signal. :13. PubMed
  116. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  117. Fujii H, et al. 2015. PLoS One. 10: 0133216. PubMed
  118. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  119. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  120. Böttcher M, et al. 2018. Oncoimmunology. 7:e1445454. PubMed
  121. Jeevan-Raj B, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.071. PubMed
  122. Lam B, et al. 2021. Cell Rep. 37:109838. PubMed
  123. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  124. Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed
  125. Volta V, et al. 2021. Nat Commun. 12:6979. PubMed
  126. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  127. Price P, et al. 2014. J Virol. 88:10840. PubMed
  128. Tzeng A, et al. 2015. Proc Natl Acad Sci U S A. 112:3320. PubMed
  129. Yamaguchi M, et al. 2016. J Leukoc Biol. 100: 131 - 141. PubMed
  130. Swee L, et al. 2016. Open Bio. 6: 160293. PubMed
  131. Lownik JC, et al. 2020. Biochem Biophys Res Commun. 522:442. PubMed
  132. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  133. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  134. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  135. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  136. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  137. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  138. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  139. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  140. Shin HS, et al. 2022. Sci Rep. 12:17605. PubMed
  141. Meyer Zu Natrup C, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  142. Toomer G, et al. 2022. Viruses. 14:. PubMed
  143. Li LH, et al. 2020. Antiviral Res. 104929:183. PubMed
  144. Jenull S, et al. 2021. Cell Reports. 36(3):109406. PubMed
  145. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  146. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  147. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  148. Alberts-Grill N, et al. 2016. J Immunol. 197(12):4651-4662. PubMed
  149. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  150. Torre S, et al. 2016. Nat Immunol. 10.1038/ni.3581. PubMed
  151. Bittner-Eddy P, et al. 2016. J Immunol. 197: 1435 - 1446. PubMed
  152. Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  153. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  154. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  155. Hartsough EJ, et al. 2019. Cell Death Dis. 10:281. PubMed
  156. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
  157. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  158. Setten E, et al. 2022. Nat Commun. 13:6499. PubMed
  159. Liu Y, et al. 2022. Cancer Discov. :. PubMed
  160. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  161. Munoz MA, et al. 2021. Elife. 10:. PubMed
  162. Gong W, et al. 2021. Oncoimmunology. 10:1997385. PubMed
  163. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  164. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  165. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  166. Witkowski M, et al. 2021. Nature. 600:295. PubMed
  167. Deng X, et al. 2021. Open Biol. 11:200340. PubMed
  168. Yu X, et al. 2021. Nature. 594:560. PubMed
  169. Park JJ, et al. 2021. Nat Commun. 12:1222. PubMed
  170. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  171. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  172. Peres A, et al. 2015. Infect Immun . 83:1587. PubMed
  173. Yoshida N, et al. 2016. Nat Commun. 7: 12993. PubMed
  174. Fang V, et al. 2016. Nat Immunol. 18:15-25. PubMed
  175. Hagen SH, et al. 2020. Cell Rep. 33:108485. PubMed
  176. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  177. Wright AKA, et al. 2017. J Allergy Clin Immunol. 140:1430. PubMed
  178. Botuyan MV, et al. 2018. Nat Struct Mol Biol. 25:591. PubMed
  179. Darzianiazizi M, et al. 2021. Cytokine X. 3:100053. PubMed
  180. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  181. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  182. Pedersen JG, et al. 2021. Front Microbiol. 12:763030. PubMed
  183. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  184. Bresque M, et al. 2022. J Biol Chem. :101711. PubMed
  185. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  186. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  187. Ruetsche D, et al. 2022. Cells. 11:. PubMed
  188. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  189. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  190. Amberg N, et al. 2016. J Invest Dermatol. 136:2140-2149. PubMed
  191. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  192. Schmitt N, et al. 2015. Mol Cancer Ther. 14: 2103-2111. PubMed
  193. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  194. Grozio A, et al. 2019. Nat Metab. 1:47. PubMed
  195. Ramsey HE, et al. 2018. Cancer Discov. 8:1566. PubMed
  196. Parameswaran P, et al. 2017. Cell Host Microbe. 10.1016/j.chom.2017.08.003. PubMed
  197. Chen Z, et al. 2022. Theranostics. 12:6242. PubMed
  198. Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed
  199. Luo X, et al. 2021. J Biol Chem. 297:101098. PubMed
  200. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  201. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  202. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  203. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  204. Denkers S 2015. J Immunol. 195: 2754-2762. PubMed
  205. Garcia-Bates T, et al. 2016. J Immunol. 196: 2870 - 2878. PubMed
  206. Davidson S, et al. 2016. EMBO Mol Med. 8: 1099 - 1112. PubMed
  207. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  208. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  209. Jordan PM, et al. 2020. Cell Rep. 33:108247. PubMed
  210. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  211. Dillon SM, et al. 2020. Bio Protoc. e3486:10. PubMed
  212. Pantelyushin S, et al. 2021. Cancers (Basel). :13. PubMed
  213. Ceholski D, et al. 2017. Stem Cell Res. 10.1016/j.scr.2017.06.015. PubMed
  214. Metzemaekers M, et al. 2017. Int J Mol Sci. 10.3390/ijms18071513. PubMed
  215. Tien S, et al. 2017. PLoS One. 10.1371/journal.pone.0181338. PubMed
  216. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  217. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  218. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  219. Stuani L, et al. 2021. J Exp Med. 218:. PubMed
  220. Zheng S, et al. 2022. Blood Cancer Discov. 3:103. PubMed
  221. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  222. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  223. Tang Y, et al. 2021. Cancer Discov. 11:3142. PubMed
  224. Borst L, et al. 2022. Int J Cancer. 150:688. PubMed
  225. Alvisi G, et al. 2022. Methods Mol Biol. 2559:243. PubMed
  226. Li FJ, et al. 2022. PLoS One. 17:e0277019. PubMed
  227. Audiger C, et al. 2020. J Immunol. 205:121. PubMed
  228. Fernandez-Castaneda A, et al. 2020. Acta Neuropathol. 139:365. PubMed
  229. Köchl R, et al. 2020. Elife. 9:00. PubMed
  230. Honarpisheh P, et al. 2020. J Neuroinflammation. 0.9625. PubMed
  231. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  232. Crisci E, et al. 2016. J Virol. 90: 4939 - 4950. PubMed
  233. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
  234. Chakraborty A, et al. 2020. Cell Rep. 32:108179. PubMed
  235. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  236. Kruse S, et al. 2018. Oncoimmunology. 8:e1524694. PubMed
  237. Louveau A, et al. 2018. Curr Protoc Immunol. 121:1. PubMed
  238. Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed
  239. Joshi N and Werner S. 2017. PLoS One. 10.1371/journal.pone.0187162. PubMed
  240. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  241. Wang Z, et al. 2022. Nat Commun. 13:5447. PubMed
  242. Romine KA, et al. 2021. Blood Cancer Discov. 2:518. PubMed
  243. Romine KA, et al. 2021. Cancer Discov. . PubMed
  244. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  245. Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
  246. Karagianni AE, et al. 2021. Sci Rep. 11:14292. PubMed
  247. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  248. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  249. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  250. Yang Y, et al. 2016. Nucleic Acids Res. 44: 4174 - 4188. PubMed
  251. Coria L, et al. 2016. J Immunol. 196: 4014 - 4029. PubMed
  252. Zhang F, et al. 2020. EMBO Mol Med. e12034:12. PubMed
  253. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  254. Rechtien A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.08.023. PubMed
  255. Yamazaki T, et al. 2020. Oncoimmunology. 9:1721810. PubMed
  256. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  257. Xing J, et al. 2021. Nat Commun. 12:2681. PubMed
  258. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  259. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  260. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  261. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  262. Hu H, et al. 2021. Cancer Immunol Res. 9:1298. PubMed
  263. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  264. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
  265. Tsang M, et al. 2020. Am J Pathol. 190:206. PubMed
  266. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  267. Brugat T, et al. 2017. Nat Microbiol. 2:16276. PubMed
  268. Andriessen E, et al. 2016. EMBO Mol Med. 8(12):1366-1379. PubMed
  269. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  270. Krämer B, et al. 2016. PLoS One. 11: 0162068. PubMed
  271. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  272. Contreras F, et al. 2016. J Immunol. 196: 4143 - 4149. PubMed
  273. Larmonier C, et al. 2016. J Biol Chem. 291: 8918-8930. PubMed
  274. Lim X, et al. 2016. Proc Natl Acad Sci U S A. 113: 1498 - 1505. PubMed
  275. Carmona SJ, et al. 2020. Oncoimmunology. 9:1737369. PubMed
  276. Haloul M, et al. 2019. Sci Rep. 9:14050. PubMed
  277. Engelbertsen D, et al. 2019. Sci Rep. 9:10608. PubMed
  278. Freire DM, et al. 2019. Mol Cell. 73:1282. PubMed
  279. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  280. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  281. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  282. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  283. Shen J, et al. 2022. Front Immunol. 13:762580. PubMed
  284. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  285. Cohen S, et al. 2015. J Immunol. 194:210. PubMed
  286. Price P, et al. 2015. J Immunol. 194:1164. PubMed
  287. Chattopadhyay A, et al. 2016. J Lipid Res. 57: 832 - 847. PubMed
  288. Dutzan N, et al. 2017. Immunity. 46(1):133-147. PubMed
  289. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  290. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  291. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  292. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  293. Fragniere AMC, et al. 2019. Sci Rep. 9:2288. PubMed
  294. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  295. Neal JT, et al. 2018. Cell. 175:1972. PubMed
  296. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  297. Zebertavage LK, et al. 2020. Sci Rep. 10:7376. PubMed
  298. Sabree SA, et al. 2021. J Immunother Cancer. 9: . PubMed
  299. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  300. Pan W, et al. 2021. J Immunol. 206:1719. PubMed
  301. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  302. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  303. Bankova AK, et al. 2022. Transplant Cell Ther. . PubMed
  304. Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed
  305. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  306. Rossignol J, et al. 2022. iScience. 25:104353. PubMed
  307. Karagianni A, et al. 2022. Front Oncol. 12:929498. PubMed
  308. Castro JT, et al. 2022. Nat Commun. 13:4831. PubMed
  309. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  310. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  311. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  312. Wang L, et al. 2020. EMBO J. 39:e104514. PubMed
  313. Ryan P, et al. 2016. Proc Natl Acad Sci U S A. 113(50):14378-14383. PubMed
  314. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  315. Tron AE, et al. 2018. Nat Commun. 9:5341. PubMed
  316. Collin R, et al. 2017. J Immunol. 10.4049/jimmunol.1600789. PubMed
  317. Teng Y, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0485-0. PubMed
  318. Huo Y, et al. 2022. Front Immunol. 13:983116. PubMed
  319. Clark GC, et al. 2022. Front Oncol. 12:913656. PubMed
  320. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  321. Rocha-Resende C, et al. 2021. J Mol Cell Cardiol. 157:98. PubMed
  322. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  323. Barington L, et al. 2022. Cells. 11:. PubMed
  324. Bendtsen SK, et al. 2022. Oncoimmunology. 11:2026020. PubMed
  325. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  326. Huo Y, et al. 2021. BMC Genomics. 22:145. PubMed
  327. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  328. Schmid M, Harris E 2014. PLoS Pathog. 10:1004541. PubMed
  329. Yoder A, et al. 2017. PLoS Pathog. 13(2):e1006226. PubMed
  330. Davey M, et al. 2017. Nat Commun. 10.1038/ncomms14760. PubMed
  331. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  332. Hagen SH, et al. 2021. STAR Protocols. 2(3):100641. PubMed
  333. Madsen D, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.12.011. PubMed
  334. Becker JR, et al. 2018. Nat Commun. 9:5406. PubMed
  335. Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed
  336. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  337. Santos NB, et al. 2021. PLoS Pathog. 17:e1009381. PubMed
  338. Miller JE, et al. 2021. JCI Insight. 6:. PubMed
  339. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  340. Lee GJ, et al. 2022. Oncoimmunology. 11:2015170. PubMed
  341. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  342. Shibata H, et al. 2021. Oncoimmunology. 10:1958589. PubMed
  343. Constant DA, et al. 2022. Immunohorizons. 6:416. PubMed
  344. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  345. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  346. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  347. Concha-Benavente F, et al. 2016. Cancer Res . 76: 1031 - 1043. PubMed
  348. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  349. Ogrinc Wagner A, et al. 2019. PLoS One. 14:e0210998. PubMed
  350. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  351. Li H, et al. 2022. Front Immunol. 13:946202. PubMed
  352. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  353. McCallion A, et al. 2022. Front Immunol. 13:961599. PubMed
  354. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  355. Alice AF, et al. 2021. Sci Rep. 11:16347. PubMed
  356. Singh AK, et al. 2022. Nat Commun. 13:878. PubMed
  357. Kumar S, et al. 2022. Gut. . PubMed
  358. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  359. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  360. Nylund P, et al. 2021. Cell Death Dis. 12:167. PubMed
  361. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  362. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  363. de Winde CM, et al. 2021. J Cell Sci. 134: . PubMed
  364. Leong Y, et al. 2016. Nat Immunol. 17:1187-1196. PubMed
  365. Ohs I, et al. 2016. Nat Commun. 7:13708. PubMed
  366. Schuldt N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1700406. PubMed
  367. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  368. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  369. Vigeland CL, et al. 2019. Physiol Rep. 7:e14019. PubMed
  370. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  371. Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
  372. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  373. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  374. Wegrecki M, et al. 2022. Nat Commun. 13:3872. PubMed
  375. Peng Z, et al. 2022. J Neuroinflammation. 19:186. PubMed
  376. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  377. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  378. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  379. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  380. Luo X, et al. 2020. J Clin Invest. 130:1635. PubMed
  381. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  382. Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed
  383. Ju X, et al. 2016. J Immunol. 197(12):4613-4625. PubMed
  384. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  385. Gouwy M, et al. 2016. PLoS One. 11:e0166006. PubMed
  386. McGuire V, et al. 2016. Sci Rep. 6:31159. PubMed
  387. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  388. Carpenter S, et al. 2016. PLoS Pathog. 12: 1005380. PubMed
  389. Jerby–Arnon L, et al. 2018. Cell. 175:984. PubMed
  390. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  391. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  392. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  393. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  394. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  395. Li M, et al. 2021. Mol Biomed. 2:41. PubMed
  396. Milich LM, et al. 2021. J Exp Med. 218:. PubMed
  397. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  398. Fucà G, et al. 2021. J Immunother Cancer. 9:. PubMed
  399. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  400. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  401. Martini E, et al. 2016. Cell Rep. 14:1062-1073. PubMed
  402. Weiss G, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.104. PubMed
  403. Neidleman J, et al. 2017. PLoS Pathog. 13(2):e1006163. PubMed
  404. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  405. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  406. Blair TC, et al. 2020. J Immunol. 204:3416. PubMed
  407. Dhimolea E, et al. 2021. Cancer Cell. 39:240. PubMed
  408. Li Y, et al. 2022. Theranostics. 12:5364. PubMed
  409. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  410. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  411. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  412. Salahudeen AA, et al. 2020. bioRxiv. . PubMed
  413. Farooq F, et al. 2016. Sci Rep. 6:27944. PubMed
  414. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  415. Tomlinson JE, et al. 2018. J Neuroinflammation. 0.753472222. PubMed
  416. Padhye A, et al. 2019. Sci Rep. 9:4819. PubMed
  417. Yuan C, et al. 2018. iScience. 11:13. PubMed
  418. Tiberti S, et al. 2022. Nat Commun. 13:6752. PubMed
  419. Bozoglu T, et al. 2022. Adv Sci (Weinh). 9:e2103867. PubMed
  420. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  421. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  422. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  423. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  424. Verma M, et al. 2021. J Exp Med. 218:. PubMed
  425. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  426. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  427. Krogmann A, et al. 2016. PLoS One. 11: 0146326. PubMed
  428. Johns S, et al. 2016. Circ Res . 119: 210 - 221. PubMed
  429. Cho SX, et al. 2020. Nat Commun. 4.481944444. PubMed
  430. Filippo Buono M, et al. 2020. Cells. 9:00. PubMed
  431. Dai H, et al. 2017. J Immunol. 10.4049/jimmunol.1700418. PubMed
  432. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  433. Friedrich V, et al. 2021. Gut Microbes. 13:1. PubMed
  434. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  435. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  436. Schaller MA, et al. 2021. JCI Insight. 6:e148003. PubMed
  437. Pan L, et al. 2021. Stem Cell Res Ther. 12:496. PubMed
  438. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  439. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  440. Spath S, et al. 2022. iScience. 25:104998. PubMed
  441. Schreurs RRCE, et al. 2021. Mucosal Immunology. 14(3):605-614. PubMed
  442. Workel HH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  443. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  444. Salahudeen AA, et al. 2020. Nature. 588:670. PubMed
  445. Hatfield J, Brown M 2015. Cell Immunol. . PubMed
  446. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  447. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  448. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  449. Kimura K, et al. 2018. Nat Commun. 9:17. PubMed
  450. Wang CJH, et al. 2022. J Biol Chem. :102714. PubMed
  451. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  452. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  453. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed
  454. Khurana P, et al. 2021. Front Immunol. 12:700374. PubMed
  455. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  456. Chakraborty A, et al. 2021. Biomaterials. 273:120796. PubMed
  457. Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed
  458. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  459. Tee YC, et al. 2021. FASEB Bioadv. 3:829. PubMed
  460. Xia L, et al. 2021. Cancer Immunol Res. 9:707. PubMed
  461. Chiou SH, et al. 2021. Immunity. 54:586. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

Is Zombie Aqua™ an equivalent to cell labeling and tracer dyes such as CellTrace™ Violet and CFSE?

Zombie Aqua™ is not a direct equivalent to such dyes because their mechanism of action and scope of application are entirely different.

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

Can I use the UV laser to stimulate Zombie Aqua™? If so, can I then use it in conjunction with BV510™?

While we typically do not test Zombie Aqua™ with the UV laser, its excitation peak suggests it is effectively excited at 355 nm. However, we would not recommend using BV510™ off the violet laser and Zombie Aqua™ off the UV laser at the same time. Due to cross-beam excitation of BV510™ by the UV laser and the violet excitation of Zombie Aqua™, this would lead to significantly increased background and excessive compensation requirements.


How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 9    Revision Date: 12/18/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account